Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

18.17 -0.40 (-2.15%)

Delayed Quote Updated: 11:23 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Legend Biotech to Host Investor Conference Call on Third-Quarter Results

November 07, 2023

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting

November 02, 2023

From Legend Biotech Corporation

Via Business Wire

Positive Outlook On Johnson & Johnson's Partner Legend Biotech: Analyst Confident On Blood Cancer Drug ↗

October 18, 2023

Legend Biotech Corporation's (NASDAQ: LEGN) partner, Johnson & Johnson (NYSE: JNJ), reported Q3 Carvykti revenues of $152 million,

Via Benzinga

Analyst Ratings for Legend Biotech ↗

October 18, 2023

Via Benzinga

The Latest Analyst Ratings for Legend Biotech ↗

August 16, 2023

Via Benzinga

The Latest Analyst Ratings for Legend Biotech ↗

July 20, 2023

Via Benzinga

The Latest Analyst Ratings for Legend Biotech ↗

June 13, 2023

Via Benzinga

Legend Biotech's Breakthrough in Multiple Myeloma Study Prompts Positive Analyst Forecast ↗

June 06, 2023

Via Benzinga

Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights

August 15, 2023

From Legend Biotech Corporation

Via Business Wire

3 Biotech Stocks That Analysts Are Drooling Over ↗

August 07, 2023

With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time.

Via InvestorPlace

Legend Biotech to Host Investor Conference Call on Second-Quarter Results

August 03, 2023

From Legend Biotech Corporation

Via Business Wire

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death ↗

June 20, 2023

A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex.

Via Investor's Business Daily

Expert Ratings for Legend Biotech ↗

May 25, 2023

Via Benzinga

Analyst's Verdict on Legend Biotech: Doubts On Commercial Execution, Long- Term Market Share ↗

May 25, 2023

Via Benzinga

Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO ↗

June 10, 2023

HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and...

Via Talk Markets

Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

June 06, 2023

From Legend Biotech Corporation

Via Business Wire

Legend Biotech Announces Participation in Upcoming Investor Conferences

June 02, 2023

From Legend Biotech

Via Business Wire

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations

May 26, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END

Via FinancialNewsMedia

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

June 05, 2023

From Legend Biotech

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023 ↗

May 25, 2023

Via Benzinga

Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

May 25, 2023

From Legend Biotech Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023 ↗

May 22, 2023

Via Benzinga

Legend Biotech Reports First Quarter 2023 Results and Recent Highlights

May 18, 2023

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

May 16, 2023

From Legend Biotech Corporation

Via Business Wire

Legend Biotech Announces Participation in Upcoming Investor Conference

May 11, 2023

From Legend Biotech Corporation

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 10, 2023

Via Benzinga

Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares

May 08, 2023

From Legend Biotech Corporation

Via Business Wire

Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine ↗

May 02, 2023

Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen

Via Benzinga

After Jumping 49% in 1 Month, Is It Too Late to Buy Legend Biotech? ↗

May 01, 2023

Legend's cell therapy seems like it's a winner, but it might be priced in already.

Via The Motley Fool

Potential Breakout Setups To Watch On Wednesday ↗

April 26, 2023

The U.S. stock market has weakened throughout Tuesday’s trading session and the major indices were sitting near session lows heading into the closing bell.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.